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ess: anlar@kablonet.coSummary Atopy is expected to be less frequent and milder in patients with early
exposure to bacterial infections because of regulatory immune mechanisms. The
definition of the hygiene hypothesis and most of the related studies have been
performed in children. In a population where both tuberculosis (tbc) and atopy are
prevalent, we investigated skin test results to allergens in adults with tbc. A
standard panel of skin-prick tests (SPTs) was applied to patients with active (n ¼ 21)
or inactive (n ¼ 72) tbc and age-matched healthy control subjects (n ¼ 76) from the
same environment. Patients also had tuberculin skin tests applied twice at 8 weeks’
interval. Patients with inactive tbc had a higher rate of allergic symptoms than those
with active tbc (Po0:01). SPTs were less frequently positive in tbc patients than in
control subjects (Po0:005). Tuberculin skin reactions were not related to SPTs
positivity. Our results suggest allergic skin test reactions may be suppressed in
patients with tbc: the interpretation of SPTs should be made accordingly.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Atopy is associated with an imbalance between
regulatory CD4+CD25+ Tcells and effector Th2 cells
against certain antigens due to genetic factors
or exposure.1,2 Within certain limitations, the
‘‘hygiene hypothesis’’ summarizes the protective
effect of infections in early life against allergic
disease.3,4 Immunotherapy in asthma aims to direct
the immune response to Th1 and increase allergen-Elsevier Ltd. All rights reserv
426 1669;
m.tr (F.Y. Anlar).specific T-regulatory cells.5 Conversely, tuberculo-
sis (tbc) is a major inducer of Th1-cells and IFN-
gamma. Epidemiologic data are compatible with an
inverse association between tbc and allergy:
children with a positive tuberculin skin test are
less likely to have atopic rhinitis than those with a
negative test, and skin-prick tests (SPTs) are more
frequently positive in children with allergic rhinitis
if tuberculin skin tests are negative.6 Mycobacterial
antigens can improve atopic dermatitis.7 However,
tbc might also exert an adjuvant effect on
responses to unrelated antigens/allergens: high
IgE levels were found in active tbc, which
decreased after treatment.8 The clinical anded.
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predisposition and the overall product of the Th1/
Th2 responses may depend on the relative pre-
dominance of genetic and environmental factors. In
this study, we investigated atopy in patients with
tbc in a population where both conditions are
prevalent.Patients and method
All tbc patients diagnosed and followed-up in
our outpatient clinic between January 2003 and
December 2003 were eligible for the study. Patients
had not been treated for tbc in the past. Active or
inactive tbc was diagnosed by bacteriologic, clin-
ical and roentgenographic findings after other
possible diagnoses were excluded and non-specific
antibiotic treatment was ineffective. Active pul-
monary tbc was defined by positive sputum culture
and/or clinical and radiologic disease, and inactive
tbc, by negative cultures and radiologically stable
findings for at least 6 months.9 All tbc patients
were examined monthly for at least 6 months, and
none received the diagnosis of respiratory allergic
disorders.
The control group consisted of healthy, age-
matched, unselected volunteers living in the same
area and within the same socioeconomical status.
After informed consent all patients and control
cases were examined by a physician blinded to
their group. A detailed questionnaire was filled out
for symptoms of allergy, exacerbating factors, past
history of atopy, and environmental characteristics
such as housing or pet ownership. The question-
naire had previously been validated in the same
clinic based on sensitivity, consistency, and respon-
siveness, and is under routine use. Comparison
between groups was concentrated on symptoms of
non-respiratory allergy in order to avoid confusion
or overlapping with tbc symptoms.Table 1 Clinical characteristics and results of tbc and c
Age (mean7SD)
Patients (n ¼ 93) 40717
Active tbc (n ¼ 21) 51715
Inactive tbc (n ¼ 72) 36716
Tbc contacted in childhood (n ¼ 28) 43723
Tbc contacted later (n ¼ 65) 39717
Control (n ¼ 76) 37711
Po0.005 between tbc and control groups.
Po0.01 between active and inactive tbc patients.SPTs using a standardized panel (ALK, Denmark)
including grass mix, tree mix, weed, fungi (alter-
naria, aspergillus, cladosporium, penicilium nota-
tum), mite (dermatophagoides pteronyssinus and
farinea), cockroach, latex, cat, and food (wheat,
egg, milk) antigens were applied accompanied by
histamine and saline as positive and negative
control, and interpreted by an allergist blinded to
the group of the patient (FYA). Tuberculin skin tests
were applied twice at 8 weeks’ interval and
interpreted 48 h later. SPT-positivity was defined
as a wheal 43mm compared to negative control.
The rate of SPT-positivity was compared between
tbc and control groups, and between active or
inactive tbc using 2-tailed t- and w2-tests as
appropriate.Results
There were 93 patients and 76 control subjects
(Table 1). The rate of SPT-positivity was 8/93 (8.6%)
in the tbc and 24/76 (31%) in the control group
(Po0:005). Active or inactive tbc patients had
similar SPT-positivity rate. The presence of allergic
symptoms or atopic family history was not asso-
ciated with SPT-positivity.
Symptoms of non-respiratory allergy had been
reported in 3 control cases and 32 patients (34%):
the latter included nasal (12 cases), gastrointest-
inal (6), skin (15), and eye (4) manifestations. The
frequency of atopic family history was similar in tbc
and control subjects. Allergic symptoms were more
common among inactive tbc (30/72) than active tbc
(2/21) (Po0:01).
A BCG scar was observed in 18% of the inactive
tbc and 17% of the active tbc cases. All tbc patients
were PPD (+) ve, with a mean7SD induration of
12.373.6mm: 14.674.2mm in tbc patients with
(n ¼ 8) and 12.073.2mm in those without (n ¼ 84)
SPT positivity (P ¼ 0:1). The size of induration wasontrol groups.
M/F Atopic history/disorder SPT positive
Personal Family
60/33 32 5 8 (8.6%)
11/9 2 — 2 (9.5%)
49/24 30 5 6 (8.3%)
19/9 4 1 3 (10.7)
41/24 33 4 5 (7.6%)
44/32 3 7 24 (31%)
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(12.573.3mm). On second testing, the induration
tended to be larger, mean 13.172.7mm, with no
difference between SPT-positive and SPT-negative,
or active and inactive tbc.Discussion
Tbc is endemic in Samsun with an incidence of
33/100.000.10 Besides, the lifetime prevalence of
asthma is 20.6%, higher than most regions in the
country.11 The relation between infections and
allergic disorders implies an effect of timing:
exposure to infections during first months of life
might protect from developing asthma, while later
exposures may exacerbate this disorder. The rela-
tion with infections is less consistent for asthma
than atopy.8 We hypothesized our tbc patients
would have a lower rate of atopic manifestations
than the normal local population especially if they
encountered tbc in early life. Our results indeed
show lower atopy rate in active and inactive tbc as
assessed by SPT. A selection bias, i.e., an over-
representation of allergic people in our control
group is unlikely because only three reported
symptoms of allergy (excluding respiratory allergy),
and the frequency of atopic family history was
similar to the tbc group. Taken together, these
results may support an immunomodulation by tbc
through prevention of Th2-dominance or non-
specific regulation by cytokines.
Inactive tbc patients had no symptoms or signs
suggestive of asthma but a higher rate of non-
respiratory (eye, nose, or skin) allergy symptoms
compared to the other groups. This observation
might imply an increase in allergy symptoms in tbc
in remission, to be explained by altered immune
balance such as a switch to Th2-type after strong
Th1-responses during active tbc, or an adjuvant
effect of tbc or its medications. Non-IgE, cell-
mediated forms of allergy might also exist in this
group: in vivo tests such as food challenge or
response to allergy medications would be useful to
assess this possibility, but were not part of the
current study. The rate of non-respiratory allergic
symptoms in control cases, 3/76, is lower than SPT
positivity: this is not unexpected since the rate of
at least one positive SPT can go up to 44–58% in the
normal population.12,13
While requiring further investigation, our obser-
vation in inactive tbc patients is in agreement with
previous studies: patients with inactive tbc showed
a higher rate of SPT-positivity to inhalant allergens
than healthy Turkish adults (48.4% vs. 25%), and ahigher rate of atopic diseases and SPT-positivity
than those with active tbc (48.45% vs. 15%).14
These results might vary between regions because
of antigenic factors such as load or presentation, or
the coexistence of other immune stimulators like
infectious agents. Among host factors, age appears
to have an important role: infections in early life,
especially the first 2 years of life are more effective
immunomodulators. The inverse relationship be-
tween tbc and asthma prevalence has been
observed at 6–7-years of age.15–17 We could not
observe an effect of age in our tbc group, but the
age of contact, retrieved retrospectively from the
history, may not have been accurately defined.
BCG vaccination is another form of immunosti-
mulation with mycobacterial antigens: however
most studies found no relation between the age
at BCG vaccination and IgE levels or asthma.18–20
Similarly, SPT-positivity was not different in PPD-
positive and negative asthmatic children in Turkey
where BCG is widely applied in early childhood.21
BCG vaccination rate in our tbc group was 18%: this
is compatible with the protection rate of the
vaccine and therefore vaccine failure suggesting
immune dysregulation is unlikely in these patients.
Early immunization with BCG might be more
efficient in children with little contact with
infections. Heredity also influences the interaction
between BCG and atopy: early BCG vaccination can
prevent the development of asthma in children
with atopic heredity.22–24 In our tbc group we did
not observe any effect of genetic predisposition as
assessed by family history. This could be due to the
overall low rate of positive family history, which
was obtained from the patient and not from direct
interview of family members. Non-infected siblings
of tbc patients might constitute an informative
control group to assess the influence of heredity.
Our investigation of the relation between SPT-
positivity and the size of PPD induration showed
slightly but insignificantly larger PPD reactions in
SPT-positive tbc cases. A previous study in Turkey
showed larger PPD-reactivity in 106 allergic chil-
dren vaccinated with BCG than non-allergic chil-
dren.25 We re-applied PPD after 8 weeks in order to
examine sensitization in atopic and non-atopic tbc
patients: 36% had larger indurations (a difference
X2mm) but without any association with SPT
results. Therefore the boosting phenomenon, oc-
curring in 12–44% of people particularly at older
ages appears intact in tbc patients and indepen-
dent of SPT reactivity.26,27
Because of the local prevalence of tbc and
asthma and the homogenous socioeconomical sta-
tus of our study groups we think most our subjects
had early exposure to infections and allergens.
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stimulations may end with predominance of one or
the other. Our results showing less SPT positivity in
patients with inactive tbc despite the presence of
allergy symptoms compared to an age-matched
control group add further data to the inverse
relation between tbc and allergy. The mechanism
of reduced SPT-positivity should be investigated in
prospective multicentric studies involving different
age and regional groups and adjusted odds ratios
for several confounders such as age, sex, or past
medical history. At present, the clinical relevance
of the observation on tbc and skin allergy consists in
caution in interpreting SPTs in tbc patients.References
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